Default company panoramic image
Logo

Chelation Partners

Dramatically enhances antibiotic efficacy by starving pathogens of essential and irreplaceable iron. Supercharges existing antibiotics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Halifax, NS, Canada
  • Currency USD
  • Founded April 2011
  • Employees 5
  • Website cpintercept.com

Company Summary

Life threatening infections are developing resistance faster than new antibiotics are discovered and approved costing hundreds of millions of dollars and thousands of lives. Chelation Partners offers a solution to this problem by starving pathogens of iron with a new family of agents improving the efficacy of drugs. These agents are extremely simple to use; just co-administer with an antibiotic. The antibiotic market in 2010 was $50+ billion.

Team

  • Photo
    Co-Founder VP Business Development

    An experienced life-sciences executive, with formal training in genetics. Involved with multiple start-up companies. Successful exits as well as guided development as well as commercialization of numerous technologies. Extensive Business Development, deal brokering, licensing and financing experience.

  • Default avatar
    Natasha Sideris
    Chief Financial Officer

    Extensive experience with start-up companies as well as large corporate firms.

  • 738d08ba 2645 43e8 8487 3ac986a9558e
    Co-Founder, President

    Bruce E. Holbein, Ph.D. in microbiology with over 25 years experience in research and commercial technology development. Bruce is a principal of Chelation Partners and inventor of the CP™ Technology. He has managed the development and commercialization of environmental and microbial biotechnologies, is inventor on 12 patents.

Previous Investors